Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1985 2
1986 1
1987 1
1988 2
1989 1
1991 2
1993 1
1994 1
1995 3
1997 1
2000 2
2001 1
2002 1
2003 1
2004 2
2005 1
2006 1
2007 1
2011 3
2012 4
2013 2
2014 2
2015 2
2016 5
2017 2
2018 4
2019 5
2020 3
2021 2
2022 2
2023 6
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study.
Hu Y, Xu X, Liu XS, He C, Ouyang YB, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Zhu Y, Graham DY, Lu NH. Hu Y, et al. Front Immunol. 2023 Jan 13;13:1049908. doi: 10.3389/fimmu.2022.1049908. eCollection 2022. Front Immunol. 2023. PMID: 36726990 Free PMC article. Clinical Trial.
Treatment naive H. pylori infected patients were randomized into two groups: 20 mg vonoprazan (VPZ) b.i.d. in combination with low-dose (1000 mg b.i.d.) or high-dose (1000 mg t.i.d) amoxicillin for 14 days. (13)C-urea breath tests were us …
Treatment naive H. pylori infected patients were randomized into two groups: 20 mg vonoprazan (VPZ) b.i.d. in combination with …
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators. Gibson CM, et al. N Engl J Med. 2024 May 2;390(17):1560-1571. doi: 10.1056/NEJMoa2400969. Epub 2024 Apr 6. N Engl J Med. 2024. PMID: 38587254 Clinical Trial.
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).
Enama ME, Ledgerwood JE, Novik L, Nason MC, Gordon IJ, Holman L, Bailer RT, Roederer M, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 011 Study Team. Enama ME, et al. PLoS One. 2014 Mar 12;9(3):e91366. doi: 10.1371/journal.pone.0091366. eCollection 2014. PLoS One. 2014. PMID: 24621858 Free PMC article. Clinical Trial.
Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration. METHODS: Sixty subjects were randomized to 6 schedules to evaluate the i.m., s.c. or i.d. route for prime injections. ...CONCLUSIONS: The patter …
Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration. METHODS: Sixty sub …
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Ratana-Amornpin S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, Graham DY, Mahachai V. Ratana-Amornpin S, et al. Helicobacter. 2023 Dec;28(6):e13019. doi: 10.1111/hel.13019. Epub 2023 Sep 18. Helicobacter. 2023. PMID: 37723133 Clinical Trial.
Subjects were randomized to: 14-day dual therapy (500 mg amoxicillin q.i.d. plus 20 mg vonoprazan b.i.d.), 14-day triple therapy (amoxicillin 1 g b.i.d., slow release clarithromycin-MR, 1 g daily plus vonoprazan 20 mg b.i.d. …
Subjects were randomized to: 14-day dual therapy (500 mg amoxicillin q.i.d. plus 20 mg vonoprazan b.i.d.), 14-da …
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Mohammadi M, et al. Dig Dis Sci. 2017 Aug;62(8):1890-1896. doi: 10.1007/s10620-017-4628-5. Epub 2017 Jun 2. Dig Dis Sci. 2017. PMID: 28577244 Free PMC article. Review.
The weighted mean cure rate for 14-day studies (six studies) using 200 mg b.i.d. furazolidone was 80% intention to treat (ITT) and 87% per protocol (PP). Studies using 100 mg b.i.d. ...Based on these data and results from China, it appears likely that …
The weighted mean cure rate for 14-day studies (six studies) using 200 mg b.i.d. furazolidone was 80% intention to treat (ITT) …
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
Graham DY, Dore MP, Lu H. Graham DY, et al. Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23. Expert Rev Anti Infect Ther. 2018. PMID: 30102559 Free PMC article. Review.
It is likely that bismuth quadruple therapy can be simplified by giving bismuth and possibly tetracycline b.i.d., possibly with fewer side effects. Concomitant therapy (a proton pump inhibitor, metronidazole, clarithromycin, amoxicillin) is ineffective with dual cla …
It is likely that bismuth quadruple therapy can be simplified by giving bismuth and possibly tetracycline b.i.d., possibly wit …
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.
Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, Sidhu JK, Ascough S, Moore SC, Mohamed N, Nunag J, King C, Leavy OC, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Harris VC, Houchen-Wolloff L, Greening NJ, Lone NI, Thorpe M, Thompson AAR, Rowland-Jones SL, Docherty AB, Chalmers JD, Ho LP, Horsley A, Raman B, Poinasamy K, Marks M, Kon OM, Howard LS, Wootton DG, Quint JK, de Silva TI, Ho A, Chiu C, Harrison EM, Greenhalf W, Baillie JK, Semple MG, Turtle L, Evans RA, Wain LV, Brightling C, Thwaites RS, Openshaw PJM; PHOSP-COVID collaborative group; ISARIC investigators. Liew F, et al. Nat Immunol. 2024 Apr;25(4):607-621. doi: 10.1038/s41590-024-01778-0. Epub 2024 Apr 8. Nat Immunol. 2024. PMID: 38589621 Free PMC article.
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 304 and VRC 305 Study Teams. Ledgerwood JE, et al. Clin Vaccine Immunol. 2012 Nov;19(11):1792-7. doi: 10.1128/CVI.05663-11. Epub 2012 Sep 5. Clin Vaccine Immunol. 2012. PMID: 22956656 Free PMC article. Clinical Trial.
There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences i …
There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccinat …
Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I, Bartels C, Graham G, Bieth B, Gautier A, Tillmann HC, Sechaud R. Demin I, et al. Int J Clin Pharmacol Ther. 2016 Jun;54(6):405-15. doi: 10.5414/CP202558. Int J Clin Pharmacol Ther. 2016. PMID: 27049057
A population pharmacokinetic (PK) analysis was performed to describe the PK profiles of indacaterol and glycopyrronium following the twice daily (b.i.d.) and once daily (o.d.) inhalation regimens as FDC or as monotherapies and to determine the effect of covariates. …
A population pharmacokinetic (PK) analysis was performed to describe the PK profiles of indacaterol and glycopyrronium following the twice d …
65 results